Cantor Fitzgerald’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-5,437
Closed -$308K 336
2024
Q4
$308K Buy
+5,437
New +$304K 0.01% 149
2023
Q4
Sell
-245,520
Closed -$14.3M 295
2023
Q3
$14.3M Sell
245,520
-10,364
-4% -$635K 0.38% 93
2023
Q2
$16.4M Sell
255,884
-2,739
-1% -$184K 0.37% 98
2023
Q1
$17.9M Sell
258,623
-574
-0.2% -$40.5K 0.38% 89
2022
Q4
$18.6M Buy
259,197
+4,712
+2% +$355K 0.4% 76
2022
Q3
$18.1M Sell
254,485
-97,508
-28% -$7.07M 0.4% 62
2022
Q2
$27.1M Buy
+351,993
New +$26.8M 0.53% 45

Other funds holding BMY

Cantor Fitzgerald's BMY Position: Q1 2025 in Review

Cantor Fitzgerald sold out of Bristol-Myers Squibb (BMY) in Q1 2025, closing a stake of 5,437 shares — an estimated $308K sold.

Cantor Fitzgerald first reported a position in BMY in Q2 2022 and held it in 7 quarters. The position peaked at $27.1M in Q2 2022. 2,477 funds tracked by Wall St. Rank hold BMY as of Q1 2025.

  • Cantor Fitzgerald reported no remaining Bristol-Myers Squibb position as of Q1 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 5,437 Bristol-Myers Squibb shares in Q1 2025, an estimated $308K.
  • Cantor Fitzgerald first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 7 quarters.
  • Cantor Fitzgerald's Bristol-Myers Squibb position peaked at $27.1M in Q2 2022.
  • 2,477 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2025.

Based on Cantor Fitzgerald's 13F filing for Q1 2025, filed 15 May 2025.